FDA Endorses Non-Animal Methods for Drug Development, Supporting PETA Scientists’ Diphtheria Therapy Strategy

The U.S. Food and Drug Administration (FDA) announced the agency would move to replace tests on animals in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods.

PETA scientists are poised to leverage this decision, which is crucial for advancing the antibody-based treatment developed by PETA Science Consortium International e.V. for diphtheria. The Science Consortium has already presented the FDA with a non-animal testing strategy for this drug, which the FDA agreed was sound. FDA’s announcement provides further momentum for the Science Consortium—and pharmaceutical companies—to proceed confidently with animal-free drug testing.